RecruitingNot ApplicableNCT06629207

Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder

Artificial Intelligence on Molecular Imaging to Predict the Risks of Parkinson's Disease for Patients With Rapid Eye Movement Sleep Behavior Disorder

Sponsor

Insel Gruppe AG, University Hospital Bern

Enrollment

20 participants

Start Date

Oct 7, 2024

Study Type

INTERVENTIONAL

Conditions

Parkinson Disease REM Sleep Behavior Disorder Dementia, Lewy Body

Summary

The study aims to systematically document the course of REM sleep behavior disorder (RBD) and investigate possible clinical and imaging biomarkers for disease progression and conversion risk to Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The study will use artificial intelligence to analyze imaging and develop a reliable method to predict and stratify patients approaching conversion to overt a-synucleinopathy. Participants will be clinically evaluated and 2 imaging procedures will be done.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using AI and brain imaging to see if researchers can predict who among people with a sleep condition called REM sleep behavior disorder (RBD) — where people act out their dreams — will go on to develop Parkinson's disease. **You may be eligible if...** - You have been diagnosed with isolated REM sleep behavior disorder (iRBD) by a movement disorder specialist - You are able to provide written consent **You may NOT be eligible if...** - You have already been diagnosed with Parkinson's disease or another brain degenerative condition - You have clear signs of Parkinson's on examination - Your RBD is caused by narcolepsy or another known condition - You have moderate to severe sleep apnea - You have abnormal neurological exam or MRI findings Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPET/CT with 18-FDG

FDG-PET scans will be acquired in a Siemens Biograph Vision Quadra PET/CT (Siemens, Germany) at 30-minute post-injection of approximately 80 MBq 18F-FDG. The duration of the acquisition is 20 minutes. The PET images will be reconstructed with the vendor's time of flight (TOF) point-spread-function (PSF) algorithm, following corrections for randoms, scatter, and decay. Attenuation correction will be performed first using low-dose CT.

DEVICESPECT : 123 I-FP-CIT (DATSCAN)

DaT-Scans will be acquired in a GE Discovery NM/CT 670 Pro™. After injection of approximately 110 MBq 123I-FP-CIT, images will be acquired within 4 h post-injection. The duration of the acquisition is 35 minutes.

DEVICEMRI

MRI examination to exclude structural brain anomalies.